 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | INT-1B3 / InteRNA Tech
Biomarker, Journal, Immunogenic cell death, Tumor microenvironment: INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death. (Pubmed Central) - Jul 15, 2024
Live cell imaging demonstrated PBMC-mediated cytotoxicity against 1B3-transfected tumor cells. These data demonstrate for the first time that miR-193a-3p induces long-term immunity against tumor development via modulation of the tumor microenvironment and induction of immunogenic cell death.
- INT-1B3 / InteRNA Tech
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 15, 2024
P1, N=25, Terminated, Sponsor: InteRNA
These data demonstrate for the first time that miR-193a-3p induces long-term immunity against tumor development via modulation of the tumor microenvironment and induction of immunogenic cell death. N=80 --> 25 | Trial completion date: Dec 2024 --> Mar 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Mar 2023; insufficient funding
- INT-1B3 / InteRNA Tech
Wilms (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_5553;
P1
To overcome this, we tested a novel lipid-nanoparticle (LNP) formulation of miR-193a-3p (INT-1B3), currently being investigated in a phase I clinical trial (NCT04675996)...Loss-of-function WT1 mutations subvert the tumor suppressor function of WT1 via failure to maintain miR-193a expression, leading to increased FLT3 expression and STAT5 signaling, subsequently impairing differentiation, increasing proliferation and disease aggressiveness in AML (Figure 1). Our findings advocate for use of FLT3 inhibition and miR-193a supplementation for treatment of WT1 mut patients, a subgroup with poor outcomes and no targeted treatment options.
- INT-1B3 / InteRNA Tech
TARGETING THE WT1MUT-MIR-193A TRANSCRIPTIONAL AXIS WITH INT-1B3, A NOVEL LIPID NANOPARTICLE-FORMULATED MIR-193A-3P MIMIC IN ACUTE MYELOID LEUKEMIA (Poster area) - May 12, 2023 - Abstract #EHA2023EHA_1876;
P1
We uncover a previously unknown regulatory mechanism between WT1 mut and miR-193a in AML cells, which provides a novel therapeutic target for a miR-193a based therapeutic for AML patients. WT1, Immunomodulation, Acute myeloid leukemia, Nanoparticle
- INT-1B3 / InteRNA Tech
Targeting the WT1mut-Mir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir-193a-3p Mimic in Acute Myeloid Leukemia (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_4200;
P1
Biweekly i.v. treatments for 8 weeks of INT-1B3 or PBS after H9M cell transplantation prevented AML formation in the INT-1B3 arm, whereas all mice in the control arm succumbed to AML, highlighting the potent anti-leukemic activity of this miRNA based therapeutic. In summary, we uncover a previously unknown regulatory mechanism between WT1mut and miR-193a in AML cells, which provides a pre-clinical rationale for a miR-193a based therapeutic for AML patients.
- | miRNA-520f / InteRNA Tech
Journal: Long Noncoding RNA SBF2-AS1 Promotes Abdominal Aortic Aneurysm Formation through the miRNA-520f-3p/SMARCD1 Axis. (Pubmed Central) - Aug 16, 2022
Therefore, BMSC exosome-derived SBF2-AS1 promotes AAA formation through the miRNA-520f-3p/SMARCD1 axis. Targeting SBF2-AS1 could serve as a promising therapeutic strategy for AAA.
- | miRNA-520f / InteRNA Tech
Journal: Long noncoding RNA WEE2-AS1 plays an oncogenic role in glioblastoma by functioning as a molecular sponge for microRNA-520f-3p. (Pubmed Central) - Aug 22, 2021
Inconclusion, WEE2-AS1 can adsorb miR-520f-3p to increase endogenous SP1expression, thereby facilitating the malignancy of GBM. Therefore, targeting theWEE2-AS1-miR-520f-3p-SP1 pathway might be a promising therapy for themanagement of GBM in the future.
- INT-1B3 / InteRNA Tech
[VIRTUAL] Phase I/Ib study with INT-1B3, a novel LNP-formulated micro-RNA (miR-193a-3p mimic) therapeutic for patients with advanced solid cancer. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2723;
P1
infusions twice a week in 21-day cycles . The first patient was enrolled on January the 14th 2021.
- | INT-1B3 / InteRNA Tech
Journal: Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology. (Pubmed Central) - Mar 23, 2021
Importantly, a novel lipid nanoparticle-based formulation of 1B3, INT-1B3, demonstrated marked anti-tumor activity as a single agent following systemic administration in tumor-bearing mice. Together, these data strongly support the development of 1B3 as a novel therapeutic agent for treatment of human cancer.
- ||| INT-1B3 / InteRNA Tech
Enrollment open, Metastases: First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 16, 2021
P1, N=80, Recruiting, Sponsor: InteRNA
Together, these data strongly support the development of 1B3 as a novel therapeutic agent for treatment of human cancer. Not yet recruiting --> Recruiting
- | INT-1B3 / InteRNA Tech
New P1 trial, Metastases: First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 19, 2020
P1, N=80, Not yet recruiting, Sponsor: InteRNA
- | miRNA-520f / InteRNA Tech
Journal: MicroRNA-520f-3p inhibits proliferation of gastric cancer cells via targeting SOX9 and thereby inactivating Wnt signaling. (Pubmed Central) - Dec 17, 2020
Together our findings thus suggest that miR-520f-3p can act to suppress GC progression, at least in part via suppressing SOX9 expression and thus disrupting Wnt/β-catenin signaling. Our results thus highlight potential novel therapeutic targets in GC worthy of future investigation.